Full-Time

Clinical Sales Specialist

CS, Baltimore, MD

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$140k - $155kAnnually

Senior

Baltimore, MD, USA

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • BA/BS or equivalent work experience
  • 5+ years sales experience required, recent endocrine relationships, specialty therapeutic, hospital, or orphan drugs sales experience highly preferred
Responsibilities
  • Build and develop professional relationships with influential high prescribers and thought leaders in the territory to enhance Corcept brand and product loyalty
  • Leverages expertise and knowledge of the therapeutic disease state, the marketplace, applicable competitors, industry, and cross-functional activities/plans to anticipate and effectively manage business opportunities and challenges
  • Develops and implements effective customer specific territory plans and communicates insights to internal stakeholders
  • Prioritizes time and effort to ensure optimal coverage of appropriate physician specialists based on opportunity and potential
  • Plan and participate in education programs and speaker dinner programs
  • Manage territory expenses/budget to support sales and marketing activities

Corcept Therapeutics focuses on developing treatments that regulate cortisol, a hormone important for stress response, metabolism, and immune function. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to improve understanding and care for cortisol-related conditions. The goal of Corcept is to advance the treatment of serious medical conditions linked to cortisol imbalance.

Company Stage

IPO

Total Funding

$42.6M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.

Help us improve and share your feedback! Did you find this helpful?